IPO registrations (S-1, F-1) · Registrants
Aptinyx Inc.
- SEC CIK
- 1674365 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2018-05-23, last 2018-06-11; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2018-06-21; declared effective 2018-06-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1801 MAPLE AVENUE, SUITE 4300, Evanston, IL 60201
- EIN
- 47-4626057
- EDGAR entity type
- operating
- Insiders and CEO pay
- Aptinyx Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2018-06-11)
- Final price
- $16.00 per share, within the range (424B4 filed 2018-06-21, an initial public offering)
- Shares sold
- 6,399,999
- Gross proceeds
- $102,399,984 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol APTX
- Lead underwriters
- J.P. Morgan; Cowen; Leerink Partners; BMO Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: APTINYX INC. EXACT (EIN (EXACT))
- Federal award recipient: APTINYX INC Fuzzy (name and state)
- Form D issuer: Aptinyx Inc. EXACT (CIK (EXACT))
- SEC filer: Aptinyx Inc. EXACT (CIK (EXACT))
- Person page: Wilbur H Gantz Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-05-23 | S-1 | S-1 (registration) | Aptinyx Inc. | 0001047469-18-004009 ↗ |
| 2018-06-11 | S-1/A | S-1/A (amendment) | Aptinyx Inc. | 0001047469-18-004374 ↗ |
| 2018-06-20 | S-1MEF | S-1MEF (added securities) | Aptinyx Inc. | 0001104659-18-041370 ↗ |
| 2018-06-20 | EFFECT | EFFECT (declared effective) | Aptinyx Inc. | 9999999995-18-001556 ↗ |
| 2018-06-21 | 424B4 | 424B4 (final prospectus) | Aptinyx Inc. | 0001047469-18-004670 ↗ |
| 2019-07-08 | EFFECT | EFFECT (declared effective) | Aptinyx Inc. | 9999999995-19-001546 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-06-11 | S-1/A | registration statement | $14.00–$16.00 | 5,333,333 | - | Nasdaq APTX | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2018-06-21 | 424B4 | final prospectus | $16.00 | 6,399,999 | $102,399,984 | Nasdaq APTX | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ADAMS STREET PARTNERS LLC | TenPercentOwner | 12 | 2018–2020 | ||
| ENRIGHT PATRICK G | Director; Director,TenPercentOwner | 15 | 2018–2022 | ||
| FHM LIFE SCIENCES VIII, L.L.C. | TenPercentOwner | 2 | 2018 | ||
| FHM LIFE SCIENCES VIII, L.P. | TenPercentOwner | 2 | 2018 | ||
| Frazier Life Sciences VIII, L.P. | TenPercentOwner | 2 | 2018 | ||
| GANTZ WILBUR H | Director | 8 | 2018–2020 | person page Fuzzy | |
| Gould Terry P | Director; Director,TenPercentOwner | 14 | 2018–2022 | ||
| Heron Patrick J | TenPercentOwner | 2 | 2018 | ||
| HOMBACH ROBERT J. | Director | 19 | 2018–2022 | ||
| Houck David | Officer | Chief Development Officer | 3 | 2018–2019 | |
| KHANNA ASHISH | Officer | CFO and CBO; CFO AND CBO | 13 | 2018–2023 | |
| KIDD ANDREW | Director,Officer; Officer | Chief Commercial Officer; PRESIDENT AND CEO; PRESIDENT & COO | 10 | 2018–2023 | |
| Koppel Adam | Director; Director,TenPercentOwner | 12 | 2018–2022 | ||
| Longitude Capital Partners II, LLC | TenPercentOwner | 2 | 2018 | ||
| Longitude Venture Partners II, L.P. | TenPercentOwner | 2 | 2018 | ||
| Madsen Torsten M. | Officer | Chief Medical Officer | 4 | 2018–2019 | |
| MOSKAL JOSEPH R. | Officer | Chief Scientific Officer | 4 | 2018–2019 | |
| New Leaf Biopharma Opportunities I, L.P. | TenPercentOwner | 2 | 2018 | ||
| New Leaf BPO Associates I, L.P. | TenPercentOwner | 2 | 2018 | ||
| New Leaf Venture Associates III, L.P. | TenPercentOwner | 2 | 2018 | ||
| New Leaf Venture Management III, L.L.C. | TenPercentOwner | 2 | 2018 | ||
| New Leaf Ventures III, L.P. | TenPercentOwner | 2 | 2018 | ||
| Ratcliffe Liam | Director; Director,TenPercentOwner | 3 | 2018–2019 | ||
| RIEDEL NORBERT G | Director,Officer | CEO; CEO and President; EXECUTIVE CHAIRMAN OF THE BOD | 14 | 2018–2023 | |
| Tammenoms Bakker Juliet | TenPercentOwner | 2 | 2018 | ||
| Topper James N | Director; Director,TenPercentOwner | 8 | 2018–2020 | ||
| Gosebruch Henry O | Director | 15 | 2019–2022 | ||
| Sherman Rachel E. | Director | 6 | 2019–2022 | ||
| Bain Capital Life Sciences Fund, L.P. | TenPercentOwner | 2 | 2020 | ||
| Bain Capital Life Sciences Investors, LLC | TenPercentOwner | 2 | 2020 | ||
| Bain Capital Life Sciences Partners, LP | TenPercentOwner | 2 | 2020 | ||
| BCIP Life Sciences Associates, LP | TenPercentOwner | 2 | 2020 | ||
| Schwartz Jeffrey Lawrence | TenPercentOwner | 2 | 2020 | ||
| Miller Joan W. | Director | 5 | 2021–2022 | ||
| O'Neill Gilmore Neil | Director | 3 | 2021–2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-12-21 | Aptinyx Inc. | Pharmaceuticals | $70,000,000 | $70,000,000 | 63 | 1 |
| 2016-05-19 | Aptinyx Inc. | Pharmaceuticals | $65,000,000 | $24,999,999 | 48 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Aptinyx Inc. | IL | Form D private offerings | CIK (EXACT) |
| SEC filer | Aptinyx Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | APTINYX INC. | EIN (EXACT) | ||
| Federal award recipient | APTINYX INC | Federal spending (USAspending) | name and state | |
| Person page | Wilbur H Gantz | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, IL first:
- APP Pharmaceuticals, Inc. IL
- XERIS PHARMACEUTICALS INC IL
- Sagent Pharmaceuticals, Inc. IL
- Wellness Center USA, Inc. IL
- Durata Therapeutics, Inc. IL
- AbbVie Inc. IL
- PharMEDium Healthcare Holdings, Inc. IL
- Baxalta Inc IL
- Accelerated Pharma, Inc. IL
- Monopar Therapeutics IL
In other datasets, the same topic (Health) in IL:
- Nonprofit: 5 LOAVES 2 FISHES FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health